Aberdeen Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
ACA
Aberdeen Group's XBI Position: Q2 2024 in Review
Aberdeen Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 203,399 shares — an estimated $19.3M sold.
Aberdeen Group first reported a position in XBI in Q4 2023 and held it in 2 quarters. The position peaked at $19.3M in Q1 2024. 761 funds tracked by Wall St. Rank hold XBI as of Q2 2024.
- Aberdeen Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
- Aberdeen Group sold 203,399 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $19.3M.
- Aberdeen Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and held it in 2 quarters.
- Aberdeen Group's State Street SPDR S&P Biotech ETF position peaked at $19.3M in Q1 2024.
- 761 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.
Based on Aberdeen Group's 13F filing for Q2 2024, filed 9 Aug 2024.